Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

@inproceedings{Horby2022BaricitinibIP,
  title={Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis},
  author={Peter W. Horby and J. R. Emberson and Marion M. Mafham and M. I. Campbell and Leon Peto and Guilherme Pessoa-Amorim and Enti Spata and Natalie Staplin and Catherine Lowe and David R. Chadwick and C E Brightling and Rachel Stewart and P. Collini and Abdul Ashish and Chloe Green and Benjamin Prudon and T. W. Felton and Anthony Kerry and John Kenneth Baillie and M. H. Buch and Jo Day and S. N. Faust and Thomas F. Jaki and Katie Jeffery and Edmund Juszczak and Matthew Knight and Wei Shen Lim and Adam Montgomery and Andrew Mumford and Kathy Rowan and Ge E. Thwaites and Richard Haynes and Martin J Landray},
  booktitle={medRxiv},
  year={2022}
}
Background: We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19. Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus… 
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
TLDR
Baricitinib was non-inferior to tocilizumab with regards to the composite outcome of mechanical ventilation or death by day 28 and the time to discharge by day28 in patients with severe COVID-19, and cost-effectiveness should be taken into account.
Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
TLDR
Compared with RMT, BCT reduces the clinical burden and utilization of intensive respiratory therapies for patients requiring low-flow oxygen or non-invasive positive pressure ventilation compared with R MT, and may thereby improve care for a patient population.
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice
TLDR
Current understanding of the effects of COVID-19 on patients with kidney disease is discussed and some of the major obstacles encountered when conducting epidemiological research in a pandemic setting are discussed.
Diagnosis and management of covid-19 in pregnancy
TLDR
Decisions regarding timing, place, and mode of delivery should be taken with a multidisciplinary team including obstetricians, physicians, anesthetists, and intensivists experienced in the care of covid-19 in pregnancy.
GWAS and meta-analysis identifies multiple new genetic mechanisms underlying severe Covid-19.
TLDR
These results provide tractable therapeutic targets for modulation of harmful host-mediated inflammation in Covid-19, and find an additional numconvincing new new genetic associations.
What is the full potential of baricitinib in treating patients with COVID-19?
This has been removed as per the suggestions from the editorsEditorial.
COVID-19 and Down syndrome: the spark in the fuel
In individuals with Down syndrome, immune dysregulation is partially caused by chromosome 21 trisomy. Here, we discuss how these immune differences may result in poorer COVID-19 outcomes, including

References

SHOWING 1-10 OF 23 REFERENCES
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
TLDR
In patients hospitalised with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) reduced 28-day mortality among patients who were seronegative at baseline.
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
TLDR
Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
TLDR
Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo, and the proportional odds of having a worse score on the eight-level ordinal scale with tofacinib, as compared with placebo.
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
TLDR
In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity, and the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks is shown.
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
TLDR
In a case series of patients with bilateral COVID‐19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS‐CoV‐2 viral load, inflammatory markers, and IL‐6 levels, and these data support further evaluation of the anti‐cytokine and anti‐viral activity of baricit inib and support its assessment in randomized trials in hospitalized CO VID‐19 patients.
...
...